Potential of activin b as a clinical biomarker in myalgic encephalomyelitis/chronic fatigue syndrome (Me/cfs)

Simple item page
dc.contributor.authorGravelsina, Sabine
dc.contributor.authorNora‐krukle, Zaiga
dc.contributor.authorVilmane, Anda
dc.contributor.authorSvirskis, Simons
dc.contributor.authorVecvagare, Katrine
dc.contributor.authorKrūmiņa, Angelika
dc.contributor.authorMurovska, Modra
dc.contributor.institutionInstitute of Microbiology and Virology
dc.contributor.institutionDepartment of Infectology
dc.date.accessioned2021-09-15T13:50:01Z
dc.date.available2021-09-15T13:50:01Z
dc.date.issued2021-08-11
dc.descriptionFunding Information: This research was funded by the Latvian Science Council?s Fundamental and Applied Research project, grant number LZP?2019/1?0380. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
dc.description.abstractReliable serum biomarkers are of immense need for diagnostic purposes of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)—a disabling and complex disease for which diagnosis is mainly based on clinical symptoms. The aim of this study was to evaluate a possible diagnostic potential of activin B by directly comparing 134 cases of ME/CFS with 54 healthy controls. Analyses of human activin B level in plasma samples were performed using a validated human activin B ELISA assay. The results of the study show that activin B levels did not differ statistically significantly between ME/CFS patients and healthy controls (p = 0.6511). No gender or age‐related differences in activin B levels were observed in the ME/CFS group and healthy controls. The level of activin B tended to decrease with increasing visual analogue scale score (r = −0.2004; p = 0.5085) nevertheless the results obtained so far does not support the clinical utility of activin B as a bi-omarker for ME/CFS.en
dc.description.statusPeer reviewed
dc.format.extent9
dc.format.extent1374451
dc.identifier.citationGravelsina, S, Nora‐krukle, Z, Vilmane, A, Svirskis, S, Vecvagare, K, Krūmiņa, A & Murovska, M 2021, 'Potential of activin b as a clinical biomarker in myalgic encephalomyelitis/chronic fatigue syndrome (Me/cfs)', Biomolecules, vol. 11, no. 8, 1189. https://doi.org/10.3390/biom11081189
dc.identifier.doi10.3390/biom11081189
dc.identifier.issn2218-273X
dc.identifier.otherunpaywall: 10.3390/biom11081189
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/6355
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85112184644&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofBiomolecules
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHuman activin B
dc.subjectME/CFS
dc.subjectVisual analogue scale
dc.subject3.1 Basic medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectBiochemistry
dc.subjectMolecular Biology
dc.subjectSDG 3 - Good Health and Well-being
dc.titlePotential of activin b as a clinical biomarker in myalgic encephalomyelitis/chronic fatigue syndrome (Me/cfs)en
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Potential_of_Activin_B_as_a_Clinical_Biomarker.pdf
Size:
1.31 MB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure